• Guy-Charles Fanneau de La Horie has more than 20 years of experience in the pharmaceutical and biotechnology industries. Prior to joining Pherecydes Pharma, he held several international management positions, namely at Schering-Plough, Biogen and IDM, in Europe and the United States. Most recently, Guy-Charles was the CEO of PathoQuest, a company specialized in pathogen identification. Between 2006 and 2013, he was CEO of Neovacs, where he led the company’s IPO in 2010.

    Prior to that, he spent eight years at Biogen, where he created and managed the subsidiaries in France and Benelux, managed the sales force in the United States and held European responsibilities. Guy-Charles is a graduate of the Ecole Nationale Vétérinaire de Lyon and the INSEAD graduate business school.

  • Thibaut du Fayet brings to the company over 20 years of experience in the pharmaceutical and life sciences industry. After obtaining an MBA from Essec Business School in 1992, he became Senior Managing Director for 6 years at Bossard-Gemini. Since 2000, he has held management positions, first at Rhône Poulenc as Director of Strategy for four years and then at BioMerieux, where he was also Marketing and Strategy Director for four years. In 2008, he joined Transgene where he spent 13 years as Vice President of Partnership Development, Alliances and Program Management.

  • Cindy is a microbiologist, expert in bacteriology. She obtained a PhD at the Pasteur Institute (Paris) in the antibiotic resistance, virulence and genetic diversity of Klebsiella. She has also worked on other major pathogens in human clinical practice, such as listeria and staphylococcus aureus.

    Prior to joining Pherecydes Pharma, Cindy developed new phage display methods and acquired substantial knowledge of bacteriophage biology and genomics. Her international experience (UMC Utrecht, Netherlands) has led her to manage R&D collaborations with industrial potential.

  • Frédérique, Doctor in Pharmacy and Engineer in Biotechnology, is a graduate of the Universities Blaise Pascal Clermont II, Montpellier I and Polytech Clermont-Ferrand. She has some twenty years of experience mainly as Quality Director in large pharmaceutical groups such as MSD, Europhartech, Carbogen Amcis and 4D Pharma PLC. She is the founder of 5QBD, a firm specialized in Quality and Business Development for biotech companies.

  • Brigitte Palestro is a graduate of the Lyon I and Paris XII Faculties of Medicine and the author of various scientific publications. She has more than 24 years of experience in the biotechnology industry. Before joining Pherecydes Pharma, she was a Medical Manager in well-known pharmaceutical groups such as Pfizer, Roche and Ipsen. She has also worked in medical consulting.

  • Céline Breda began her career at Sanofi Pasteur in France and the United States. In 2005, she joined the biotech company Valneva, where she headed up pharmaceutical operations for over eight years. Following the sale of Valneva’s bioproduction site in Nantes in 2013, she took over the Operations Management of this unit, initially for the company BE Vaccines, a subsidiary of the Indian pharmaceutical group Biological E, and then, from 2019, for the company Naobios, a subsidiary of CDMO Clean Biologics.

Supervisory Board


  • Didier Hoch
    Chairman - Independent
  • Maryvonne Hiance
    Vice-Chairwoman - Independente
  • Franck Lescure
    Permanent representative of Elaia Partners
  • Leila Nicolas
    Permanent representative of Go Capital
  • Guy Rigaud
  • Robert Sebbag
  • Eric Leire

Know more about our partnerships